Allele and genotype frequencies of CYP2C9 within an Iranian population (Mazandaran)

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 7, 2012, Pages 817-821

  Hashemi Soteh, Seyed Mohammad Bagher ^a   Shahabi Majd, Naghi ^a   Gholizadeh, Ali Reza ^b   Shiran, Mohammad Reza ^b  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9;

ARTICLE; ETHNICITY; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; IRAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; IRAN; MALE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 84863950636     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0301     Document Type: Article

References (42)

1. Adithan C, Gerard N, Vasu S, et al. (2003) Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol 59:707-709. (Pubitemid 37498209)
2. Allabi AC, Gala JL, Desager JP, et al. (2003) Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 56:653-657. (Pubitemid 37491717)
3. Amini-Shirazi N, Ghahremani MH, Ahmadkhaniha R, et al. (2010) Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicol Mech Methods 20:452-457.
4. Arvanitidis K, Ragia G, Iordanidou M, et al. (2007) Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 21:419-426. (Pubitemid 47084032)
5. Azarpira N, Namazi S, Hendijani F, et al. (2010) Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran. Pharmacol Rep 62:740-746.
6. Bae JW, Kim HK, Kim JH, et al. (2005) Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60:418-422.
7. Bozina N, Granic P, Lalic Z, et al. (2003) Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 44:425-428. (Pubitemid 37098309)
8. Bravo-Villalta HV, Yamamoto K, Nakamura K, et al. (2005) Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur J Clin Pharmacol 61:179-184. (Pubitemid 40768549)
9. Dickmann LJ, Rettie AE, Kneller MB, et al. (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 60:382-387. (Pubitemid 32678304)
10. Dorado P, Cavaco I, Caceres MC, et al. (2008) Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol 64:967-970.
11. Gaedigk A, Casley WL, Tyndale RF, et al. (2001) Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 79:841-847. (Pubitemid 33033541)
12. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. (2003) Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59:303-312. (Pubitemid 37100349)
13. Garcia-Martin E, Martinez C, Ladero JM, et al. (2001) High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 57:47-49. (Pubitemid 32391412)
14. Hashemi Soteh M, Peake IR, Marsden L, et al. (2007) Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electro-phoresis: a comparison of fluorescent and manual techniques. Haematologica 92:550-553. (Pubitemid 350144301)
15. Higashi MK, Veenstra DL, Kondo LM, et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690-1698. (Pubitemid 34289221)
16. Hong X, Zhang S, Mao G, et al. (2005) CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 61:627-634.
17. Ingelman-Sundberg M, Sim SC, Gomez A, et al. (2007) Influence of cytochrome P450 polymorphisms on drug therapies: phar-macogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526. (Pubitemid 350116943)
18. Kimura M, Ieiri I, Mamiya K, et al. (1998) Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit 20:243-247. (Pubitemid 28248841)
19. Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251-263. (Pubitemid 34596790)
20. Lierena A, Berecz R, Dorado P, et al. (2003) CYP2C9 gene and susceptibility to major depressive disorder. Pharmacoge-nomics J 3:300-302. (Pubitemid 37428195)
21. LLerena A, Dorado P, O'Kirwan F, et al. (2004) Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J 4:403-406. (Pubitemid 39600058)
22. Martinez C, Garcia-Martin E, Blanco G, et al. (2005) The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 59:62-69.
23. Mas S, Crescenti A, Vidal-Taboada JM, et al. (2005) Simultaneous genotyping of CYP2C9*2, *3, and 5¢ flanking region (C-1189T) polymorphisms in a Spanish population through a new min-isequencing multiplex single-base extension analysis. Eur J Clin Pharmacol 61:635-641.
24. Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356:1667-1671.
25. Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525-538. (Pubitemid 28270907)
26. Nasu K, Kubota T, Ishizaki T (1997) Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 7:405-409. (Pubitemid 27427552)
27. Peyvandi F, Spreafico M, Karimi M, et al. (2002) Allele frequency of CYP2C9 gene polymorphisms in Iran. Thromb Haemost 88:874-875. (Pubitemid 35345350)
28. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83-448. (Pubitemid 34311090)
29. Scordo MG, Aklillu E, Yasar U, et al. (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447-450. (Pubitemid 32939447)
30. Scordo MG, Pengo V, Spina E, et al. (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702-710. (Pubitemid 36021009)
31. Stubbins MJ, Harries LW, Smith G, et al. (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacoge-netics 6:429-439. (Pubitemid 26380099)
32. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349. (Pubitemid 26288624)
33. Tanira MO, Al-Mukhaini MK, Al-Hinai AT, et al. (2007) Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Community Genet 10:32-37. (Pubitemid 46005799)
34. Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816-1819. (Pubitemid 30661066)
35. Wang SL, Huang J, Lai MD, et al. (1995) Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 5:37-42.
36. Xie HG, Prasad HC, Kim RB, et al. (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 54:1257-1270. (Pubitemid 35284252)
37. Yang JQ, Morin S, Verstuyft C, et al. (2003) Frequency of cyto-chrome P450 2C9 allelic variants in the Chinese and French populations. Fundam Clin Pharmacol 17:373-376. (Pubitemid 36774173)
38. Yasar U, Eliasson E, Dahl ML, et al. (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628-631. (Pubitemid 29290517)
39. Yoon YR, Shon JH, Kim MK, et al. (2001) Frequency of cyto-chrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 51:277-280.
40. Zand N, Tajik N, Moghaddam AS, et al. (2007) Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin Exp Pharmacol Physiol 34:102-105. (Pubitemid 46069593)
41. Zhou SF, Zhou ZW, Huang M (2010) Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 278:165-188.
42. Zhou SF, Zhou ZW, Yang LP, et al. (2009) Substrates, inducers, inhibitors and structure-activity relationships of human Cy-tochrome P450 2C9 and implications in drug development. Curr Med Chem 16:3480-3675.